PrisMax V3
National Institutes of Health · NATIONAL INSTITUTES OF HEALTH OLAO
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 26-008236 in this department, oldest first.
- Sep 24, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
With the establishment of the new Pediatric Intensive Care Unit (PICU), the CC needs to add one PrisMax Continuous Renal Replacement Therapy (CRRT) machine to their existing fleet of 5 Prismax CRRT. The CC successfully integrated the PrisMax with the hospital�s EHR, CRIS in 2020. PrisMax Systems are intended for: Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload. Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicat… (show all)
ed. The TherMax Blood Warmer Accessory is indicated for warming returning blood flow. DESCRIPTION OF THE SUPPLIES AND SERVICES REQUIRED, INCLUDING THE DELIVERY SCHEDULE AND/OR THE PERIOD OF PERFORMANCE and DOLLAR VALUE OF THE ACQUISITON. Procurement is for: One (1) PrisMax V3 US One (1) TherMax Blood Warmer One (1) PrisMax Warmer Arm Kit
Who won similar work
25 award notices on SAM.gov in the last 24 months. Matched by: Same agency (National Institutes of Health), same industry group (NAICS 3345).
Single-winner award sizes (25): middle half $37K to $230K, median $65K; range $14K to $5.9M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| AGILENT TECHNOLOGIES INC · $A · $7.4B | 2 | $401K | Jul 24, 2025 |
| GOVERNMENT SCIENTIFIC SOURCE INC | 2 | $283K | Dec 17, 2025 |
| 10X GENOMICS, INC. · $TXG · $616.9M | 2 | $77K | Sep 22, 2025 |
| GE PRECISION HEALTHCARE LLC | 1 | $5.9M | Sep 17, 2025 |
| FEI COMPANY | 1 | $1.8M | Sep 22, 2025 |
| BRUKER BIOSPIN CORP · $BRKR · $3.5B | 1 | $1.4M | Sep 18, 2025 |
| BECTON, DICKINSON AND COMPANY · $BDX · $22.5B | 1 | $1.3M | Jan 3, 2025 |
| BRUKER NANO, INC · $BRKR · $3.5B | 1 | $230K | Aug 14, 2026 |
| Sony Biotechnology Inc. | 1 | $227K | Aug 17, 2026 |
| NEWPORT CORP | 1 | $212K | Jul 8, 2026 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $A reported $7.4B revenue (12 months to Jul 31, 2026). The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. SEC filing
- $TXG reported $616.9M revenue (12 months to Jun 30, 2026). The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. SEC filing
- $BRKR reported $3.5B revenue (12 months to Jun 30, 2026). The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. SEC filing
- $BDX reported $22.5B revenue (12 months to Jun 30, 2026). The median single-winner award in these 25 past awards, $65K, is under 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 9, 2026Revvity Health Sciences, Inc.$21KAutomated Cell Counter and AnalyzerNo listed company matched (Materiality N/A)
- Sep 25, 2026NIKON INSTRUMENTS INC$40K66--Warming Box/Enclosure for Nikon Eclipse Ti-2 AX coNo listed company matched (Materiality N/A)
- Aug 17, 2026Sony Biotechnology Inc.$227K66--NIMH: Purchase order for One (1) Microfluidic BaseNo listed company matched (Materiality N/A)
- Aug 14, 2026BRUKER NANO, INC$230K66--NIMH: Purchase order for One (1) Miniaturized HeadMateriality: <0.01% of $BRKR revenue (Low) SEC
- Aug 7, 2026BITTIUM USA INC.$48K66--NIMH: Non Competitive Combined Synopsis for FarosNo listed company matched (Materiality N/A)
- Jul 10, 2026BECKMAN COULTER, INC$31K66--Purchase Order for two (2) Hematology AnalysersNo listed company matched (Materiality N/A)
- Jul 10, 2026AMUZA INC.$115K66--NIMH: Purchase order for four (4) wireless fiber pNo listed company matched (Materiality N/A)
- Jul 8, 2026NEWPORT CORP$212K66--RFQ for One (1) Tunable Laser Multi-Photon MicroscNo listed company matched (Materiality N/A)
- Jul 8, 2026SR RESEARCH LIMITED$37K66--NIMH: Purchase Order for One (1) EyeLink 1000 PlusNo listed company matched (Materiality N/A)
- Jul 8, 2026PARSE BIOSCIENCES, INC.$67K66--PO for One (1) Evercode WT v3 with UDI Plate andNo listed company matched (Materiality N/A)
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 8 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 0 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (0 filings)
- 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
- $45K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 0 bills named on the past winners' lobbying filings
- 0 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 4 of the past winners are listed companies
- 0 insider buys and 8 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.